How to Lower Blood Pressure on Cycle With Telmisartan and Nebivolol

Your resting BP creeps from 122/78 at week zero to 142/92 by week six. You've added test, EQ, and a little tren. The forum says telmisartan. Your GP says lisinopril. Reddit says nebivolol because it won't kill your pump. Nobody tells you how to choose, what dose, or what labs to pull two weeks after starting.

This guide does. It's the decision tree no harm reduction blog actually writes. You get the four mechanisms that drive on-cycle hypertension, the two antihypertensives that fit enhanced athletes best, the lab schedule that catches bad outcomes early, and the hard line where stopping the cycle beats stacking another drug.

Why your blood pressure rises on cycle

The HAARLEM study followed 100 men through real-world AAS cycles. Mean systolic BP rose 6.87 mmHg, diastolic 3.17 mmHg, and both returned to baseline within a year of stopping (Smit et al., 2021). LV mass climbed 28 grams during cycle, scaling with weekly dose, and 3D ejection fraction dropped almost five percentage points (Smit et al., 2021, Echocardiography paper). Fluid retention showed up in 56 percent of users. Those are the averages. Stack tren, EQ, and an oral and the curve gets nasty fast.

Four mechanisms drive the rise. They stack additively, which is why the harshest cycles produce the worst numbers.

Erythrocytosis and viscosity

Testosterone and 19-nor compounds push haematocrit and haemoglobin up by stimulating renal EPO, suppressing hepcidin, and acting directly on bone marrow progenitors. A systematic review of drug-induced erythrocytosis put prevalence as high as 66.7 percent in men on prescription testosterone, with IM routes, higher doses, and older age all pushing the rate up (Liu et al., 2025). Hct scales blood viscosity exponentially in large vessels, and viscosity drives mean arterial pressure (Cinar et al., 1999). Boldenone is notorious for this. Testosterone enanthate and oxymetholone are next.

RAAS activation and mineralocorticoid agonism

Anabolic steroids upregulate the cardiac renin-angiotensin system. In a 10-week rat study of nandrolone, LV ACE activity climbed 28 percent and angiotensin II plus AT1 receptor expression both rose, with losartan blocking the effect (Rocha et al., 2007). Worse, 19-nor steroids bind the mineralocorticoid receptor as full agonists, where progesterone antagonises it (Funder and Adam, 1981). That means nandrolone, trenbolone, and other 19-nors drive sodium retention and potassium loss through the same receptor aldosterone uses. Chowdhury and Mahanta confirmed it in mice. Nandrolone raised serum aldosterone and sodium with potassium holding steady, the textbook mineralocorticoid signature (Chowdhury and Mahanta, 2017).

Fluid retention from aromatising orals and estradiol

Dianabol aromatises to 17α-methylestradiol, a potent estrogen that upregulates angiotensinogen and tubular sodium reabsorption. Anadrol drives similar retention through direct estrogenic activity at high doses. Estradiol itself elevates BP via volume expansion when it climbs out of range. The trap is crashing E2 to fix the bloat. AI overuse worsens lipids and accelerates the cardiovascular damage you were trying to avoid. The fix is a real antihypertensive, not anastrozole.

Sympathetic activation and vasoconstriction

Long-term AAS users show reduced baroreflex sensitivity, lower parasympathetic HRV, higher sympathetic tone, and a sympathovagal balance that tracks directly with hypertension and cardiac hypertrophy (Barbosa Neto et al., 2018; Dos Santos et al., 2018). Supraphysiological doses also blunt nitric oxide synthesis and raise noradrenaline, angiotensin II, and thromboxane. Clenbuterol stacks an acute beta-2 agonist load on top of an already activated sympathetic system, with case reports of myocardial ischaemia in young lifters.

The Baggish cardiac MRI work is what closes the argument. Long-term AAS users showed mean LVEF 50.6 percent versus 59.1 percent in non-using weightlifters, and active users carried coronary plaque volumes that scaled with cumulative lifetime dose (Baggish et al., 2010; Baggish et al., 2017). Chronic uncontrolled BP on cycle is the bridge between a 6 mmHg average rise and that endpoint.

My BP just hit X/Y on cycle, what do I do today

Forget the spreadsheets for a minute. Sit down for five minutes, take a validated upper-arm cuff reading, average three readings one minute apart, and find your number on this tree.

Under 130/80, MAP under 100. Do nothing pharmacological. Recheck weekly. Watch haematocrit, watch resting heart rate, watch sodium intake. CoQ10 and taurine both have meta-analysis-level BP data and belong in your on-cycle support stack regardless.

130 to 140 over 80 to 90. Lifestyle first, hard. Drop sodium to 2 to 3 g, sleep seven plus hours, log home BP daily for two weeks, drop pre-workout stims, donate blood if Hct is above 52. Recheck. If you're three weeks in and still drifting up, start telmisartan 20 to 40 mg.

140 to 150 over 90 to 95. This is the action band. Start telmisartan 40 mg in the morning, get a baseline BMP plus cystatin C and urine ACR, recheck BP in two weeks. If resting heart rate is above 80 or you're running tren or clen, add nebivolol 2.5 to 5 mg.

Above 150/95 or any reading above 160 systolic. Stop adding harsh compounds. Telmisartan 40 to 80 mg, nebivolol 5 mg, full lab panel, GP appointment this week. If you're symptomatic (headache, chest tightness, visual changes) this is an ED visit, not a forum thread. Above 180/120 is a hypertensive crisis. Go to a hospital.

Refractory above 150/95 after four weeks of telmisartan plus nebivolol at max dose. Time to stop the cycle. The drug stack isn't keeping up with what you're putting in.

Telmisartan: dose, mechanism, and why it's first line

Telmisartan blocks the angiotensin II type 1 receptor, which prevents angiotensin from constricting arterioles and triggering aldosterone release. Standard half-life across ARBs is six to nine hours. Telmisartan's is roughly 24, which gives you true once-daily 24-hour BP coverage, including the early morning surge window when most cardiovascular events fire.

Then there's the bonus. Telmisartan is a partial PPAR-gamma agonist at clinically achievable doses, about 25 to 30 percent of pioglitazone's activity, and it's the only ARB with that property at therapeutic concentrations (Benson et al., 2004). PPAR-gamma activation improves insulin sensitivity, raises adiponectin, and modestly drops triglycerides and fasting glucose. For users running growth hormone, MK-677, or oral 17-AAs, that's a real second mechanism, not a marketing line.

Telmisartan 40 mg versus 80 mg on cycle

Start at 40 mg in the morning. The first BP reduction shows within three hours, most of the effect is in by two weeks, and maximum effect lands around four weeks. Do not judge the response before then. If you're at week three and BP is still drifting, do not panic-titrate. Wait for the four-week mark, then move to 80 mg if you haven't hit your target.

If you're sensitive, on the lighter side, or stacking with nebivolol from day one, 20 mg is a reasonable starting dose. It's still antihypertensive but gives you headroom.

The ceiling is 80 mg. Above that, you're adding a second drug class, not pushing telmisartan further.

Telmisartan versus losartan versus lisinopril

Losartan works but it's a 6 to 9 hour drug. You'll need 50 to 100 mg split twice daily for true 24-hour coverage, and it has none of the PPAR-gamma benefit. Cheap and effective, fine fallback if telmisartan isn't available, but not first choice.

Lisinopril is an ACE inhibitor, not an ARB. It blocks angiotensin production rather than receptor binding. Equally renoprotective on outcome trials. Two practical problems for athletes: the bradykinin cough hits 5 to 35 percent of users, which is hell during cardio, and the angioedema risk is real if low. ARBs sidestep both.

The cardinal rule: never combine ACE plus ARB. ONTARGET tested ramipril plus telmisartan against either alone in 25,620 patients. The combination raised hyperkalaemia, hypotension, and AKI without adding any cardiovascular benefit (Yusuf et al., 2008; Mann et al., 2008). Pick one, max it out, then add a different class.

Renoprotection and LVH reversal

The ARB and ACEi class earns its first-line status from two landmark trials. RENAAL showed losartan cut the doubling of creatinine by 25 percent and ESRD progression by 28 percent in diabetic nephropathy patients, independent of BP effect (Brenner et al., 2001). IRMA-2 showed irbesartan 300 mg dropped progression from microalbuminuria to overt nephropathy by 70 percent over two years (Parving et al., 2001). Translation for AAS users: blocking AT1 protects the kidney through the same pathway that's already getting hammered by elevated creatinine, urine ACR, and androgenic RAAS upregulation.

ARBs also reverse left ventricular hypertrophy more aggressively than older drug classes. A 12-month telmisartan trial cut LV mass index 27.5 percent versus 9.7 percent on atenolol at the same BP target. For long-term AAS users with concentric LVH on echo, that's a structural rescue argument, not just a pressure number.

Nebivolol: the beta-blocker that won't kill your pump

Nebivolol is the only beta-blocker with this combination: highly selective beta-1 blockade plus nitric oxide-mediated vasodilation. The d-isomer blocks beta-1, the l-isomer triggers endothelial NO synthase. That second mechanism is what separates it from metoprolol, atenolol, and propranolol, which crush peripheral perfusion and leave you with cold hands, dead legs, and erectile dysfunction.

The MR NOED study put 12 weeks of metoprolol succinate 95 mg per day against nebivolol 5 mg per day in hypertensive men aged 40 to 55. Same BP reduction. The metoprolol group dropped their IIEF erectile function score by 0.92. The nebivolol group did not (Brixius et al., 2007). A 2025 meta-analysis of four RCTs in 397 patients confirmed it: IIEF-5 mean difference 1.81 in favour of nebivolol regardless of baseline ED status (Lu et al., 2025). The Doumas trial showed 69 percent of hypertensive men with baseline ED improved after switching from atenolol or metoprolol to nebivolol (Doumas et al., 2006).

Insulin and lipid neutrality matter on cycle too. Ayers and colleagues put 46 metabolic syndrome patients on metoprolol or nebivolol for 12 weeks at equivalent BP reduction. Metoprolol cut insulin sensitivity, raised PAI-1, and raised oxidative stress markers. Nebivolol did none of that (Ayers et al., 2012). On harsh cycles where HbA1c, HDL, and PAI-1 are already moving the wrong way, an older beta-blocker is gasoline.

Predel and team also showed nebivolol preserves VO2max and exercise capacity in physically active hypertensives, where traditional beta-blockers tank both (Predel et al., 2001). If you train hard, this matters.

Dosing nebivolol on cycle

Start 2.5 mg or 5 mg per day. Most users land at 5 mg. Titrate at two to four week intervals. 10 mg if you're escalating a harsh tren or clen cycle. Maximum label dose is 40 mg but you should never need it on a properly managed cycle. Once daily morning is standard. Don't stop abruptly. Rebound HR and BP are real.

Reach for nebivolol when:

• Resting HR is above 80 bpm
• Palpitations on tren, clen, or T3
• ACE or ARB cough or hyperkalaemia is limiting your ARB dose
• Baseline anxiety or stim load is pushing sympathetic tone

Telmisartan plus nebivolol is the standard combination for harsh-cycle BP escalators. The ARB handles RAAS and volume. The beta-blocker handles HR and sympathetic drive. They stack cleanly with no overlapping metabolic penalty.

Compound-specific picks

One BP drug doesn't fit every stack. Match the antihypertensive to the dominant mechanism for what you're actually running.

Trenbolone

Three mechanisms in one compound. It raises haematocrit, activates the mineralocorticoid receptor through 19-nor structure, and pushes sympathetic tone hard. There's no AI rescue for the MR-driven retention. Pick: telmisartan 40 to 80 mg plus nebivolol 5 mg. Avoid ACE inhibitors because the cough during cardio is intolerable. Watch potassium closely. Watch creatinine closely. This is the compound that gives tren its nephrotoxicity reputation, and the cascade starts with BP.

Boldenone (EQ)

Pure HCT and viscosity story. Aldosterone-neutral. Pick: telmisartan 40 mg plus phlebotomy at Hct above 52. Donating 500 mL drops Hct three to five percentage points and gives you a one-shot mechanical win the drug can't deliver on its own. See the hematocrit lowering guide for the full phlebotomy protocol.

Oral 17-AAs (dbol, anadrol, superdrol)

Aromatisation, hepatic VLDL pressure, fast fluid retention within one to two weeks. Pick: telmisartan plus amlodipine 5 mg if ankle edema is the dominant complaint. Calcium channel blockers fix the peripheral pooling that orals love to produce. If BP stays refractory, drop the oral early. There's no win in pushing a four-week dbol kickstart to six weeks when your BP is at 150/95.

Nandrolone and NPP

Aldosterone elevation is confirmed in animal models. Pick: telmisartan first. Spironolactone is mechanistically attractive (direct MR blockade) but the evidence on combining it with an AI is mixed and rarely studied in this population. See the nandrolone bloodwork guide for the prolactin and aldosterone story.

Testosterone (TRT base)

Baseline HCT-driven plus mild RAAS contribution. Pick: telmisartan 20 to 40 mg. Usually all you need. Most TRT users plateau on Hct within six months. If yours is still climbing at month nine, see the TRT haematocrit guide for the deeper workup.

Growth hormone and MK-677

ENaC-mediated sodium retention is the GH-axis mechanism (Kamenicky et al., 2008). Loop diuretics fail here because the sodium escapes downstream of the loop. Pick: telmisartan. The PPAR-gamma bonus directly addresses the insulin resistance GH and MK-677 produce, which is the second pillar of the cardiometabolic problem (Benndorf et al., 2006). See the GH insulin resistance article and the MK-677 blood sugar protocol for the glucose monitoring half.

Clenbuterol

Sympathetic agonist. HR and palpitations are the main complaint, not BP per se. Pick: nebivolol 2.5 to 5 mg. Beta-1 selectivity controls the HR without blunting beta-2 fat loss as severely as non-selective agents. Or just stop the clen. Most lifters who try to medicate clen are running it too long.

GLP-1 agonists (semaglutide, tirzepatide, retatrutide)

The optimistic close. Tirzepatide cut SBP by nearly 7 mmHg over 72 weeks in SURMOUNT-1, with about 70 percent of the effect mediated by weight loss and 30 percent independent (Krumholz et al., 2024). An individual patient meta-analysis of semaglutide trials showed 5 mmHg SBP reduction (Kennedy et al., 2024). These are the only PED-adjacent compounds that actively lower BP. Cruisers stacking a low-dose GLP-1 onto TRT often see BP drop without any antihypertensive at all.

Monitoring protocol on an ARB

Starting telmisartan without baseline labs in an AAS user is malpractice on yourself. Without a baseline, a two-week creatinine bump is uninterpretable.

Baseline panel before starting

• BMP: sodium, potassium, bicarbonate, urea, creatinine, eGFR
• Cystatin C: AAS users carry muscle-mass-inflated creatinine. Cystatin C-based eGFR catches the subclinical AAS nephrotoxicity that creatinine misses. See the cystatin C article for why this matters more in our population than in sedentary patients (Ozkurt et al., 2023).
• Urine ACR: earliest signal of glomerular damage. Without it, you can't tell whether new proteinuria at month three is the drug, the cycle, or both.
• NT-proBNP: baseline cardiac strain reference. AAS, GH, and high-dose insulin all drive concentric LVH long before symptoms.
• CRP if cardiometabolic load is high

Recheck at 2 weeks

The KDIGO 2024 guideline recommends rechecking BMP and BP within two to four weeks of initiation (Stevens et al., 2024). Use this three-bucket triage.

Green light. Creatinine rise under 10 percent, potassium under 5.0 mmol/L. Continue, recheck at three months.

Yellow light. Creatinine rise 10 to 25 percent, potassium 5.0 to 5.4 mmol/L. Continue but tighten the diet (cut high-K leafy greens and electrolyte powders), hydrate, recheck in two more weeks. Schmidt's 2017 BMJ cohort of 122,363 patients showed even modest creatinine rises carry graded risk, so monitor closely (Schmidt et al., 2017).

Red light. Creatinine rise above 30 percent, potassium 5.5 mmol/L or higher, or eGFR drop above 25 percent. Hold the ARB. Investigate volume depletion, NSAID use, bilateral renal artery stenosis, or subclinical AAS nephropathy.

The Bakris paradox: why a 20 to 30 percent creatinine bump is the drug working

Bakris and Weir reviewed 12 RCTs in 1,102 patients and showed that creatinine rises up to 30 percent that stabilise within the first two months are associated with long-term renal preservation, not injury. Patients with baseline creatinine above 1.4 mg/dL had a 55 to 75 percent relative risk reduction in renal disease progression when ACEi was continued through the bump (Bakris and Weir, 2000). The mechanism is intraglomerular pressure reduction (efferent arteriolar dilation), which is exactly what protects the kidney long term. Counter-intuitive but real. The kidney looks worse on paper while it's actually getting safer.

Hyperkalaemia thresholds

• Potassium above 5.0 mmol/L at baseline: don't start the ARB yet. Fix the diet first.
• Potassium 5.0 to 5.4: counsel on diet, recheck in two weeks (Momoniat et al., 2019).
• Potassium 5.5 or higher: reduce dose by half, recheck in one to two weeks.
• Potassium 6.0 or higher: hold the drug.

The SCREAM project showed about 1.7 percent of patients hit potassium above 5.5 within the first year of RASi initiation, concentrated in those with eGFR under 30, heart failure, diabetes, baseline potassium in the upper half of range, NSAIDs, or potassium-sparing diuretics (Bandak et al., 2017). Bodybuilders often hit several of those risk factors. High-K diets from chicken, potatoes, leafy greens, and electrolyte powders. NSAIDs for joint pain. Spironolactone for gyno. The compound risk is the under-appreciated piece.

Long-term cadence

On a stable dose, recheck BMP and BP every three to six months. Any time you change cycle, change diuretic protocol, add an NSAID, or start a new compound, recheck within two weeks of the change.

How long until telmisartan actually works

Forum panic at week one is the most common adverse reaction. Here's the week-by-week reality.

Days 1 to 3. Onset of antihypertensive effect within three hours of the first dose. Most users won't notice anything subjectively.

Week 1. Subtle BP drop, 3 to 5 mmHg systolic typical. You won't see it on a single reading because day-to-day variation swamps the signal.

Week 2. Most of the effect is in. Average daily home BP should be 8 to 12 mmHg lower systolic than baseline. This is also when you pull the BMP recheck.

Week 4. Maximum effect. If you're not at goal here, titrate to the next dose level. If you're at 80 mg telmisartan and still above 140/90, that's the cue to add nebivolol or pivot to a second class, not to push telmisartan higher.

Stopping abruptly is fine. ARBs do not have the rebound profile of beta-blockers. You can stop telmisartan day-of without dose tapering.

MAP and pulse pressure: targets for athletes

Single SBP and DBP numbers miss two signals that actually matter.

Mean arterial pressure. MAP = DBP + (SBP minus DBP) divided by 3. Example: 142/92 gives MAP = 92 + (142 minus 92)/3 = 92 + 16.7 = 108.7 mmHg. Normal range is 70 to 100. Above 100 means your organs are seeing sustained perfusion pressure that drives end-organ damage. Most enhanced athletes chasing aggressive BP control on cycle should aim for MAP under 100, ideally under 95.

Pulse pressure. SBP minus DBP. Same 142/92 example gives PP = 50, which is on the edge. Target under 60. A wider PP signals arterial stiffness and is a meaningful early flag in young AAS users, especially long-cycle veterans. Sustained PP above 60 in a 35-year-old lifter is a cardiology referral, not a forum question.

Track both at home along with raw SBP and DBP. A validated upper-arm cuff (Omron HEM-7156T, Withings BPM Core, anything ESH/AHA validated) gives you reliable numbers. Take readings seated, back supported, feet flat, five minutes of rest, no caffeine or training in the 30 minutes prior, arm at heart level. Two to three readings one minute apart, averaged. Morning before meds and evening before bed.

When to stop cycling instead of medicating

The hard truth nobody writes. Antihypertensives are not infinite. There is a point where the answer is to drop the harsh compound, not stack a third drug class.

Stop the cycle when:

• BP stays above 150/95 after four weeks on telmisartan 80 mg plus nebivolol 10 mg
• Hct stays above 54 after phlebotomy plus telmisartan
• Creatinine bump is above 30 percent and not stabilising at four weeks
• NT-proBNP doubles from baseline
• Symptoms appear: headaches, visual changes, exertional chest tightness, palpitations that don't resolve with the beta-blocker
• Potassium can't be kept below 5.5 even with dietary adjustment and dose reduction

The HAARLEM data is clear that most BP rises reverse within a year of stopping. The Baggish work is equally clear that long-term users accumulate structural damage. Repeated harsh cycles with persistently uncontrolled BP are how you transition from "high BP on cycle, normal off" to permanent hypertension and concentric LVH. Don't be that statistic. There is no compound worth a 20-point bump in your resting SBP that won't come back down.

Key takeaways

• On-cycle BP rises through four additive mechanisms: erythrocytosis, RAAS activation, fluid retention from aromatisation, and sympathetic vasoconstriction. Match the drug to the mechanism.
• Telmisartan 40 mg in the morning is the default first pick. Long half-life, renoprotective, partial PPAR-gamma activity for the insulin resistance side of the problem.
• Add nebivolol 5 mg when resting HR is above 80 or you're running tren or clen. It's the only beta-blocker that doesn't tank your pump, lipids, or erectile function.
• Never combine ACE plus ARB. ONTARGET settled the question.
• Pull a baseline BMP, cystatin C, urine ACR, and NT-proBNP before starting any antihypertensive on cycle.
• A 20 to 30 percent creatinine bump at the two-week recheck is the drug working, not failing. A bump above 30 percent or potassium above 5.5 is the stop signal.
• Most BP medication takes two weeks for most of the effect and four weeks for maximum effect. Don't titrate before then.
• MAP under 100 and pulse pressure under 60 are the real targets, not just SBP and DBP.
• When telmisartan 80 plus nebivolol 10 can't hold you below 150/95, the cycle is the problem, not the drug.

---

References

1. Smit, D. L., Buijs, M. M., de Hon, O., den Heijer, M., and de Ronde, W. (2021). Positive and negative side effects of androgen abuse. The HAARLEM study: A one-year prospective cohort study in 100 men. Scandinavian Journal of Medicine and Science in Sports, 31(2), 427-438. PubMed
2. Smit, D. L., Voogel, A. J., den Heijer, M., and de Ronde, W. (2021). Anabolic androgenic steroids induce reversible left ventricular hypertrophy and cardiac dysfunction. Echocardiography results of the HAARLEM study. Frontiers in Reproductive Health, 3, 732318. PubMed
3. Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., Lu, M. T., Hoffmann, U., and Pope, H. G. Jr. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, 135(21), 1991-2002. PubMed
4. Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., Picard, M. H., Hutter, A. M. Jr., and Pope, H. G. Jr. (2010). Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation: Heart Failure, 3(4), 472-476. PubMed
5. Liu, J., Chin-Yee, B., Ho, J., Lazo-Langner, A., Chin-Yee, I. H., Iansavitchene, A., and Hsia, C. C. (2025). Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review. Blood Advances, 9(9), 2108-2118. PubMed
6. Cinar, Y., Demir, G., Paç, M., and Cinar, A. B. (1999). Effect of hematocrit on blood pressure via hyperviscosity. American Journal of Hypertension, 12(7), 739-743. PubMed
7. Barbosa Neto, O., da Mota, G. R., De Sordi, C. C., et al. (2018). Long-term anabolic steroids in male bodybuilders induce cardiovascular structural and autonomic abnormalities. Clinical Autonomic Research, 28(2), 231-244. PubMed
8. Dos Santos, M. R., Sayegh, A. L. C., Armani, R., et al. (2018). Resting spontaneous baroreflex sensitivity and cardiac autonomic control in anabolic androgenic steroid users. Clinics (Sao Paulo), 73, e226. PubMed
9. Rocha, F. L., Carmo, E. C., Roque, F. R., et al. (2007). Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats. American Journal of Physiology: Heart and Circulatory Physiology, 293(6), H3575-H3583. PubMed
10. Funder, J. W., and Adam, W. R. (1981). 19-Nor progesterone is a mineralocorticoid agonist. Endocrinology, 109(1), 313-315. PubMed
11. Chowdhury, P., and Mahanta, R. (2017). Effect of administration of nandrolone decanoate upon aldosterone concentration and serum Na+/K+ levels in albino mice. Cardiovascular and Hematological Agents in Medicinal Chemistry, 14(3), 160-166. PubMed
12. Yusuf, S., Teo, K. K., Pogue, J., et al. (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine, 358(15), 1547-1559. PubMed
13. Mann, J. F., Schmieder, R. E., McQueen, M., et al. (2008). Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study). Lancet, 372(9638), 547-553. PubMed
14. Brenner, B. M., Cooper, M. E., de Zeeuw, D., et al. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine, 345(12), 861-869. PubMed
15. Parving, H. H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., and Arner, P. (2001). The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine, 345(12), 870-878. PubMed
16. Benson, S. C., Pershadsingh, H. A., Ho, C. I., et al. (2004). Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma modulating activity. Hypertension, 43(5), 993-1002. PubMed
17. Benndorf, R. A., Rudolph, T., Appel, D., et al. (2006). Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism, 55(9), 1159-1164. PubMed
18. Brixius, K., Middeke, M., Lichtenthal, A., Jahn, E., and Schwinger, R. H. G. (2007). Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study). Clinical and Experimental Pharmacology and Physiology, 34(4), 327-331. PubMed
19. Lu, Y., Li, L., Li, Q., and Sun, G. (2025). Effect of nebivolol on erectile function: A systematic review and meta-analysis of randomized controlled trials. Journal of Sexual Medicine. PubMed
20. Doumas, M., Tsakiris, A., Douma, S., et al. (2006). Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian Journal of Andrology, 8(2), 177-182. PubMed
21. Ayers, K., Byrne, L. M., DeMatteo, A., and Brown, N. J. (2012). Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension, 59(4), 893-898. PubMed
22. Predel, H. G., Mainka, W., Schillings, W., et al. (2001). Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. Journal of Human Hypertension, 15(10), 715-721. PubMed
23. Bakris, G. L., and Weir, M. R. (2000). Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Archives of Internal Medicine, 160(5), 685-693. PubMed
24. Schmidt, M., Mansfield, K. E., Bhaskaran, K., et al. (2017). Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: Cohort study. BMJ, 356, j791. PubMed
25. Stevens, P. E., Ahmed, S. B., Carrero, J. J., et al. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105(4S), S117-S314. PubMed
26. Momoniat, T., Ilyas, D., and Bhandari, S. (2019). ACE inhibitors and ARBs: Managing potassium and renal function. Cleveland Clinic Journal of Medicine, 86(9), 601-607. PubMed
27. Bandak, G., Sang, Y., Gasparini, A., et al. (2017). Hyperkalemia after initiating renin-angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) Project. Journal of the American Heart Association, 6(7), e005428. PubMed
28. Ozkurt, S., Ozakin, E., Gungor, H., and Yalcin, A. U. (2023). Assessment of renal function of bodybuilders using anabolic androgenic steroids and diet supplements. Cureus, 15(8), e43058. PubMed
29. Kamenicky, P., Viengchareun, S., Blanchard, A., et al. (2008). Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology, 149(7), 3294-3305. PubMed
30. Krumholz, H. M., de Lemos, J. A., Sattar, N., et al. (2024). Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart, 110(19), 1165-1171. PubMed
31. Kennedy, C., Hayes, P., Cicero, A. F. G., et al. (2024). Semaglutide and blood pressure: an individual patient data meta-analysis. European Heart Journal, 45(38), 4124-4134. PubMed